IP Library Granted Patent US 9,693,977
Granted Patent B2
US 9,693,977 · App. 14/777,476 · Granted Jul 4, 2017

Method of increasing the quantity of colonic T regulatory cells via G-coupled protein receptor 43

Inventors: Wendy S. Garrett (Brookline, MA); Patrick M. Smith (Foxborough, MA)
Assignee: President and Fellows of Harvard College
A61K31/19
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,693,977
App. No.
14/777,476
Granted
Jul 4, 2017
Kind
B2
Abstract

Disclosed herein are compositions and methods that are useful for inducing the development of regulatory T cells (T reg ). Such compositions and methods are useful for treating inflammatory conditions and in particular inflammatory conditions affecting the gastrointestinal tract of a subject. In certain embodiments, the present inventions generally relate to short chain fatty acids and the discovery that such short chain fatty acids may be used to treat and/or prevent inflammatory conditions by enhancing the size and immune function of a subject's endogenous T reg population.

Claims (10)

1. A method of increasing the quantity of colonic regulatory T cells (cT reg ) in a subject in need thereof comprising contacting a regulatory T cell (T reg ) with an effective amount of a composition to thereby increase the quantity of cT reg , wherein the composition comprises one or more short chain fatty acid (SCFA) compounds capable of modulating a G-coupled protein receptor 43 (GPR43), and wherein the composition is administered to the subject orally.

2. The method of claim 1 , wherein the effective amount of the composition achieves a concentration of at least 5 mM of the one or more short chain fatty acid (SCFA) compounds within the lumen of the subject's gastrointestinal tract.

3. The method of claim 1 , wherein the regulatory T cell (T reg ) express the G-coupled protein receptor 43 (GPR43).

4. The method of claim 1 , wherein the regulatory T cell (T reg ) is Foxp3 + .

5. The method of claim 1 , wherein the regulatory T cell (T reg ) is IL-10 + .

6. The method of claim 1 , wherein the effective amount of the composition achieves a concentration of at least 10 mM of the one or more short chain fatty acid (SOFA) compounds within the lumen of the subject's gastrointestinal tract.

7. The method of claim 1 , wherein the compounds are selected from the group consisting of formic acid, acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid and isovaleric acid.

8. A method of increasing expression of Foxp3 and IL-10 in Foxp3 + and IL-10 + regulatory T cells (T reg ) in a subject in need thereof, wherein the T reg express a G-coupled protein receptor 43 (GPR43), wherein the method comprises contacting the T reg with an effective amount of a composition comprising one or more short chain fatty acids and thereby increasing expression of Foxp3 and IL-10, and wherein the composition is administered to the subject orally.

9. The method of claim 8 , wherein the regulatory T cells (T reg ) are colonic regulatory T cells (cT reg ).

10. The method of claim 8 , wherein the step of contacting the regulatory T cells (T reg ) with one or more short chain fatty acids inhibits histone deacetylase (HDAC).

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2016
From: GARRETT, WENDY S.; SMITH, PATRICK M.
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 037518/0221 →
CONFIRMATORY LICENSE Recorded Oct 15, 2015
From: HARVARD UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 036869/0118 →
Continuity (2)
Provisional Application 61800299 · Mar 15, 2013
Related Publication 20160038447A1 · Feb 11, 2016